Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim) is a fixed-dose combination of the long-acting beta 2 agonist (LABA) olodaterol and the gold-standard long-acting muscarinic antagonist (LAMA) tiotropium. The LABA/LAMA combination received US and EU approvals for use in chronic obstructive pulmonary disease (COPD) in Q2 2015.
Datamonitor Healthcare forecasts Stiolto Respimat to capture significant share in the COPD market and drive sales in the LABA/LAMA class. This is based on the drug’s promising efficacy data to date and Boehringer Ingelheim’s strong marketing capabilities and extensive experience in the respiratory market as a result of its well-established LAMA, Spiriva (tiotropium). Boehringer Ingelheim is expected to invest heavily to encourage patient switching from Spiriva to Stiolto Respimat in an attempt to protect its respiratory franchise and minimize competition from the numerous LABA/LAMAs and triple-combination therapies that are reaching the COPD market.
LIST OF FIGURES
13 Figure 1: Stiolto Respimat for COPD – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Stiolto Respimat for COPD
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Stiolto Respimat for COPD
18 Figure 4: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Stiolto Respimat drug profile
7 Table 2: Stiolto Respimat Phase III data in COPD
10 Table 3: Stiolto Respimat Phase III and Phase IIIb/IV data in COPD
12 Table 4: Stiolto Respimat’s ongoing Phase IV trial in COPD
19 Table 5: Stiolto Respimat sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.